Radioimmunotherapy of human colon carcinoma xenografts using a 213Bi-labeled domain-deleted humanized monoclonal antibody.

The data presented within this paper is the first report of a humanized domain-deleted monoclonal antibody (HuCC49DeltaCH2) to be utilized in a radioimmunotherapeutic (RIT) application with 213Bi. An initial study indicated that 111In-HuCC49DeltaCH2 targets the subcutaneously implanted human colon carcinoma xenograft, LS-174T, when injected via a peritoneal route. The HuCC49DeltaCH2 was then radiolabeled with 213Bi, an alpha-emitting radionuclide with a half-life of 45.6 minutes, and evaluated for therapeutic efficacy. Dose titration studies indicated that a single dose of 500-1000 microCi, when injected by an intraperitoneal route, resulted in the growth inhibition or regression of the tumor xenograft. The radioimmunotherapeutic effect was found to be dose-dependent. Specificity of the therapeutic efficacy was confirmed in a subsequent experiment with athymic mice bearing TAG-72 negative MIP (human colorectal) xenografts. A preliminary study was also performed to assess a multiple-dose administration of 213Bi-HuCC49DeltaCH2. Doses (500 microCi) were administered at 14-day intervals after tumor implantation. A reduction in volume and/or delay in tumor growth was evident following the second and third injections of 213Bi-HuCC49DeltaCH2. As further validation of the use of 213Bi-HuCC49DeltaCH2 for RIT, a study using 131I was conducted. The overall survival of mice receiving 213Bi-HuCC49DeltaCH2 was greater than those that received 131I-HuCC49DeltaCH2.

[1]  J. Schlom,et al.  A novel monoclonal antibody design for radioimmunotherapy. , 2003, Cancer biotherapy & radiopharmaceuticals.

[2]  S. Adelstein,et al.  Bystander effect produced by radiolabeled tumor cells in vivo , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[3]  J. Humm,et al.  Targeted α particle immunotherapy for myeloid leukemia , 2002 .

[4]  T. Waldmann,et al.  Pretargeting radioimmunotherapy of a murine model of adult T-cell leukemia with the alpha-emitting radionuclide, bismuth 213. , 2002, Blood.

[5]  T. Waldmann,et al.  Vascular-Targeted Radioimmunotherapy with the Alpha-Particle Emitter 211At , 2002, Radiation research.

[6]  L. Chappell,et al.  In vivo comparison of macrocyclic and acyclic ligands for radiolabeling of monoclonal antibodies with 177Lu for radioimmunotherapeutic applications. , 2002, Nuclear medicine and biology.

[7]  D. Goldenberg.  The role of radiolabeled antibodies in the treatment of non-Hodgkin's lymphoma: the coming of age of radioimmunotherapy. , 2001, Critical reviews in oncology/hematology.

[8]  M. Brechbiel,et al.  The development of the alpha-particle emitting radionuclides 212Bi and 213Bi, and their decay chain related radionuclides, for therapeutic applications. , 2001, Chemical reviews.

[9]  E. Kremmer,et al.  Highly specific tumor binding of a 213Bi-labeled monoclonal antibody against mutant E-cadherin suggests its usefulness for locoregional alpha-radioimmunotherapy of diffuse-type gastric cancer. , 2001, Cancer research.

[10]  S. Mirzadeh,et al.  In vivo evaluation of bismuth-labeled monoclonal antibody comparing DTPA-derived bifunctional chelates. , 2001, Cancer biotherapy & radiopharmaceuticals.

[11]  C. Cordon-Cardo,et al.  An α-Particle Emitting Antibody ([213Bi]J591) for Radioimmunotherapy of Prostate Cancer , 2000 .

[12]  L. Chappell,et al.  Delivery of the alpha-emitting radioisotope bismuth-213 to solid tumors via single-chain Fv and diabody molecules. , 2000, Nuclear medicine and biology.

[13]  D. Milenic.  Radioimmunotherapy: designer molecules to potentiate effective therapy. , 2000, Seminars in radiation oncology.

[14]  R. Meredith,et al.  Clinical radioimmunotherapy. , 2000, Seminars in radiation oncology.

[15]  T. Back,et al.  Radioimmunotherapy of nude mice with intraperitoneally growing ovarian cancer xenograft utilizing 211At-labelled monoclonal antibody MOv18. , 2000, Anticancer research.

[16]  Y. Erdi,et al.  Pharmacokinetics and dosimetry of an alpha-particle emitter labeled antibody: 213Bi-HuM195 (anti-CD33) in patients with leukemia. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[17]  D. Scheinberg,et al.  Alpha-emitting bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti-CD33 antibodies: pharmacokinetics, bioactivity, toxicity and chemistry. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[18]  I. Pastan,et al.  Aminosyn II effectively blocks renal uptake of 18F-labeled anti-tac disulfide-stabilized Fv. , 1998, Cancer research.

[19]  S. Kennel,et al.  Vascular targeted radioimmunotherapy with 213Bi-An α-particle emitter , 1998 .

[20]  P. Hand,et al.  A CDR-grafted (humanized) domain-deleted antitumor antibody. , 1997, Cancer biotherapy & radiopharmaceuticals.

[21]  M. Brechbiel,et al.  An Improved Generator for the Production of 213Bi from 225Ac , 1997 .

[22]  R. Levy,et al.  Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[23]  D. Bigner,et al.  Radioimmunotherapy with α-Particle Emitting Radioimmunoconjugates , 1996 .

[24]  N. Kotite,et al.  Lysine reduces renal accumulation of radioactivity associated with injection of the [177Lu]alpha-[2-(4-aminophenyl) ethyl]-1,4,7,10-tetraaza-cyclodecane-1,4,7,10-tetraacetic acid-CC49 Fab radioimmunoconjugate. , 1995, Cancer research.

[25]  Wendy S. Becker,et al.  Reduction of the renal uptake of radiolabeled monoclonal antibody fragments by cationic amino acids and their derivatives. , 1995, Cancer research.

[26]  T. Waldmann,et al.  Radioimmunotherapy of Nude Mice Bearing a Human Interleukin 2 Receptor α-expressing Lymphoma Utilizing the α-emitting Radionuclide-conjugated Monoclonal Antibody 212Bi-anti-Tac , 1994 .

[27]  T. Yokota,et al.  Microautoradiographic analysis of the normal organ distribution of radioiodinated single-chain Fv and other immunoglobulin forms. , 1993, Cancer research.

[28]  P. Thorpe,et al.  Targeting the vasculature of solid tumors , 1993 .

[29]  T. Yokota,et al.  Differential metabolic patterns of iodinated versus radiometal chelated anticarcinoma single-chain Fv molecules. , 1992, Cancer research.

[30]  M. Brechbiel,et al.  Effective α-Particle-mediated Radioimmunotherapy of Murine Leukemia , 1992 .

[31]  M. Brechbiel,et al.  Spectrophotometric method for the determination of a bifunctional DTPA ligand in DTPA-monoclonal antibody conjugates. , 1992, Bioconjugate chemistry.

[32]  T. Yokota,et al.  Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. , 1992, Cancer research.

[33]  M. Brechbiel,et al.  Synthesis of C-functionalized trans-cyclohexyldiethylenetriaminepenta-acetic acids for labelling of monoclonal antibodies with the bismuth-212 α-particle emitter , 1992 .

[34]  T. Yokota,et al.  Construction, binding properties, metabolism, and tumor targeting of a single-chain Fv derived from the pancarcinoma monoclonal antibody CC49. , 1991, Cancer research.

[35]  S. Larson.  Choosing the right radionuclide and antibody for intraperitoneal radioimmunotherapy. , 1991, Journal of the National Cancer Institute.

[36]  K. Johnson,et al.  Combined immunohistochemical and autoradiographic analyses of antigen/antibody interactions in tumor xenograft models. , 1991, Laboratory investigation; a journal of technical methods and pathology.

[37]  J. Schlom,et al.  Monoclonal antibody-based therapy of a human tumor xenograft with a 177lutetium-labeled immunoconjugate. , 1991, Cancer research.

[38]  S. Mirzadeh,et al.  Improved in vivo stability and tumor targeting of bismuth-labeled antibody. , 1990, Cancer research.

[39]  M. Brechbiel,et al.  212Bismuth linked to an antipancreatic carcinoma antibody: model for alpha-particle-emitter radioimmunotherapy. , 1988, Journal of the National Cancer Institute.

[40]  J L Humm,et al.  Dosimetric aspects of radiolabeled antibodies for tumor therapy. , 1986, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[41]  M A Markwell,et al.  A new solid-state reagent to iodinate proteins. I. Conditions for the efficient labeling of antiserum. , 1982, Analytical biochemistry.

[42]  P. Fraker,et al.  Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphrenylglycoluril. , 1978, Biochemical and biophysical research communications.